Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492552 | 1.00 | MAPT (0.78) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL4905569 | 0.98 | MAPT (0.76) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL28070128 | 0.93 | MAPT (0.69) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL3529060 | 0.91 | MAPT (0.82) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL13964419 | 0.91 | MAPT (0.66) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL7292289 | 0.89 | RAB9A (0.67) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL25392583 | 0.89 | MAPT (0.72) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL683708 | 0.88 | KDM4E (0.70) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL864819 | 0.88 | MEN1 (1.00) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 | |
| SCHEMBL8213545 | 0.87 | MAPT (0.70) | MAPTMEN1KMT2ANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60099133-A | — | — | None | — | — | JP | disclosed |
| WO-2023174773-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| US-11634544-B2 | Photoaligning materials | Rolic Technologies AG (CH) | 2023-04-25 | — | — | US | disclosed |
| US-20210340330-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| US-10696795-B2 | Photoaligning materials | Rolic Technologies AG (CH) | 2020-06-30 | — | — | US | disclosed |
| EP-3374467-B1 | COMPOSITIONS OF PHOTO-ALIGNABLE MATERIALS | ROLIC TECH AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10558089-B2 | Photoalignment composition | ROLIC AG (CH) | 2020-02-11 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| US-20120076952-A1 | PHOTOCROSSLINKABLE MATERIALS | ROLIC AG (CH) | 2012-03-29 | — | — | US | disclosed |
| EP-2308827-A1 | Photocrosslinkable materials | Rolic AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308826-A1 | Photocrosslinkable materials | Rolic AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305632-A1 | Photocrosslinkable materials | Rolic AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305631-A1 | Photocrosslinkable materials | Rolic AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20100266814-A1 | PHOTOALIGNMENT COMPOSITION | ROLIC AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20100048849-A1 | PHOTOCROSSLINKABLE MATERIALS COMPRISING ALICYCLIC GROUP | ROLIC AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20080293888-A1 | Photocrosslinkable Materials | ROLIC AG (CH) | 2008-11-27 | — | — | US | disclosed |
| JP-S6099133-A | MOLDED ARTICLE OF POLYAMIDE-IMIDE | AGENCY OF IND SCIENCE & TECHNOL | 1985-06-03 | — | — | JP | disclosed |
| US-RE30352-E | AMIDE OR UREA CONTAINING SALT, SULFURIC ACID, HYDROFLUORIC ACID, OR HALO- OR METHANESULFONIC ACID | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | MAPT 2745/4885MEN1 2477/4885KMT2A 4427/4885 |
| US-20100048849-A1 | PHOTOCROSSLINKABLE MATERIALS COMPRISING ALICYCLIC GROUP | DDC, ALAD, DYNC1LI1 | MAPT 1424/4885MEN1 2579/4885KMT2A 770/4885 |
| US-20080293888-A1 | Photocrosslinkable Materials | DDC, PARG, ALAD | MAPT 295/4885MEN1 676/4885KMT2A 666/4885 |
| US-20120076952-A1 | PHOTOCROSSLINKABLE MATERIALS | DDC, PARG, ALAD | MAPT 295/4885MEN1 676/4885KMT2A 666/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | MAPT 689/4885MEN1 4699/4885KMT2A 4342/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | MAPT 2830/4885MEN1 4875/4885KMT2A 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.